Epigral | Business Upturn

Epigral Q4 Results: Revenue jumps 17.3% YoY to Rs 736.16 crore, net profit falls 6.8%

Aman Shukla — Sat, 02 May 2026 10:34:18 +0000

Epigral reported a mixed set of numbers for the quarter ended March 31, 2026 (Q4 FY26), where revenue growth remained strong on a year-on-year (YoY) basis, but profitability came under pressure due to rising expenses.

On the operational front, revenue from operations stood at ₹736.16 crore in Q4 FY26 compared to ₹627.63 crore in Q4 FY25, registering a solid growth of 17.3%. Total income also increased by 16.6% YoY to ₹735.59 crore from ₹631.03 crore in the corresponding quarter last year. However, other income turned negative at ₹(0.57) crore versus ₹3.40 crore YoY, slightly impacting overall earnings.

The cost side remained elevated during the quarter. Total expenses rose sharply by 25.0% YoY to ₹625.07 crore, compared to ₹499.97 crore in Q4 FY25. This increase in expenses outpaced revenue growth, which weighed on margins.

As a result, profit before tax (PBT) declined 15.7% YoY to ₹110.52 crore from ₹131.06 crore. Profit after tax (PAT) also fell 6.8% YoY to ₹80.95 crore compared to ₹86.89 crore in the same quarter last year.

For the full year FY26, Epigral reported a relatively stable top line but weaker profitability. Revenue from operations came in at ₹2,527.18 crore compared to ₹2,550.13 crore in FY25, marking a marginal decline of 0.9%. Total income also dipped 0.9% YoY to ₹2,542.16 crore.

Annual expenses increased by 8.7% YoY to ₹2,200.36 crore from ₹2,025.24 crore, continuing to exert pressure on earnings. Consequently, profit before tax dropped significantly by 36.7% YoY to ₹341.80 crore from ₹540.10 crore.

Despite the sharp fall in PBT, profit after tax declined by a relatively moderate 7.2% YoY to ₹331.97 crore compared to ₹357.69 crore in FY25, supported by lower tax outgo during the year.

Epigral shares fall sharply over 6% as Q2 net profit drops 37% YoY to Rs 51.2 crore, EBITDA down 25.6%

Aman Shukla — Mon, 10 Nov 2025 08:05:58 +0000

Epigral Ltd shares dropped more than 6% in early trade on Monday after the company posted a steep decline in its second-quarter (Q2 FY2025) earnings. The sharp fall came as investors reacted to a 37% year-on-year (YoY) drop in net profit, reflecting pressure on margins and weaker operational performance.

The company reported a consolidated net profit of ₹51.2 crore, compared to ₹81.3 crore in the same quarter last year. Revenue from operations also declined 6.2% YoY, coming in at ₹587.3 crore, down from ₹626 crore in Q2 FY2024.

On the operational front, EBITDA fell 25.6% to ₹132 crore, as against ₹178 crore in the corresponding period last year. The EBITDA margin contracted by 600 basis points to 22.6% from 28.5%.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Epigral Q2 Results: Revenue falls 6.2% YoY to Rs 587.3 crore, net profit down 37%

Aman Shukla — Mon, 10 Nov 2025 08:02:01 +0000

Epigral Ltd shares fell sharply after the company reported a steep 37% year-on-year (YoY) decline in its net profit for the second quarter of FY2025. The company’s consolidated net profit dropped to ₹51.2 crore, compared to ₹81.3 crore in the same period last year.

Revenue also took a hit, slipping 6.2% YoY to ₹587.3 crore, down from ₹626 crore in Q2 FY2024. Operational performance weakened as well, with EBITDA falling 25.6% to ₹132 crore, compared to ₹178 crore a year ago.

The company’s EBITDA margin contracted by 600 basis points, dropping to 22.6% from 28.5% last year, indicating pressure on profitability amid softer pricing and higher input costs.

The disappointing quarterly numbers triggered a sharp sell-off in Epigral’s stock, which tanked over 6% on the BSE following the results announcement.

Disclaimer: This article is for informational purposes only. It is not intended to be investment advice or a recommendation to buy or sell any stock. Readers are advised to consult their financial advisor before making any investment decisions.

Epigral shares fall over 6% as Q1 revenue drops 6.8% YoY to Rs 615 crore, Ebitda down 7.4%

Aman Shukla — Mon, 04 Aug 2025 04:19:11 +0000

Epigral Limited shares tumbled over 6% in morning trade on Monday after the company released its financial results for the quarter ended June 30, 2025 (Q1 FY26). As of 9:46 AM, the shares were trading 6.23% lower at Rs 1,834.40.

The integrated chemical manufacturer reported a revenue of ₹615 crore for Q1 FY26, marking a 6% year-on-year decline compared to ₹654 crore in the same quarter last year. The decline in topline was attributed to lower realizations and muted demand in select segments.

EBITDA for the quarter came in at ₹163 crore, down 7% YoY, though EBITDA margins remained steady at 27%. This was supported by continued operational efficiency and a stronger focus on product mix optimization.

Net profit stood at ₹160 crore, which includes a one-time deferred tax liability benefit of ₹81 crore. Adjusted for this item, profit after tax (PAT) was ₹79 crore—lower than the ₹86 crore reported in Q1 FY25.

On the operational front, plant utilization stood at 73% during the quarter. The company’s Return on Capital Employed (ROCE) improved to 24% from 21% a year ago, signaling improved profitability and capital efficiency.

In terms of financial strength, Epigral’s Net Debt-to-EBITDA ratio saw a significant improvement, dropping to 0.6x from 1.6x in the previous year—indicating a healthier balance sheet and reduced leverage.

The Derivatives & Specialty Chemicals segment remained a key contributor, accounting for 50% of the company’s total revenue in the quarter.

Epigral Q1 Results: Revenue falls 6% YoY to Rs 615 crore, net profit up 86% YoY

Aman Shukla — Sat, 02 Aug 2025 08:17:24 +0000

Epigral Limited, one of India’s leading integrated chemical manufacturers, has announced its financial results for the quarter ended June 30, 2025 (Q1FY26). The company reported a revenue of ₹615 crore, reflecting a 6% year-on-year decline compared to ₹654 crore in the same quarter last year (Q1FY25).

Despite the dip in top-line performance, EBITDA stood at ₹163 crore, down 7% YoY. However, EBITDA margins remained steady at 27%, supported by continued operational efficiency and a strategic focus on product mix.

Net profit (PAT) came in at ₹160 crore, which includes a deferred tax liability benefit of ₹81 crore. Excluding this, the adjusted PAT stood at ₹79 crore, slightly lower than ₹86 crore in Q1FY25.

Operationally, plant utilization stood at 73% during the quarter. Return on Capital Employed (ROCE) improved to 24% from 21% a year earlier, driven by better profitability. Additionally, the company’s Net Debt/EBITDA ratio dropped significantly to 0.6x, compared to 1.6x in the previous year, reflecting a stronger balance sheet position.

Revenue from the company’s Derivatives & Specialty Chemicals segment contributed 50% to the overall revenue.

Epigral acquires 26% stake in renewable energy SPV for Rs 21.38 crore

Aman Shukla — Wed, 04 Jun 2025 05:43:34 +0000

Epigral Limited has announced the execution of agreements to invest in a renewable energy project in Gujarat. On June 4, 2025, the company entered into a Share Subscription and Shareholder’s Agreement with Prozeal Green Power Private Limited and Pro-Zeal Green Power Ten Private Limited. Additionally, it signed an Energy Supply Agreement with Pro-Zeal Green Power Ten Private Limited to source 19.80 MW of Wind Solar Hybrid (WSH) power as a captive consumer.

As part of this transaction, Epigral will subscribe to at least 26% of the securities—comprising equity and optionally convertible debentures—of Pro-Zeal Green Power Ten Private Limited, a special purpose vehicle (SPV) formed to develop and operate the WSH power project. The investment will be made in one or more tranches, totaling approximately ₹21.38 crore, and will be through cash consideration.

The SPV was incorporated on January 2, 2025, and is yet to begin commercial operations. Its current paid-up capital is ₹1 lakh. Following the transaction, Pro-Zeal Green Power Ten will become an associate of Epigral. The ownership in the SPV will be held in the ratio of 26:74 by Epigral and Prozeal Green Power Private Limited, respectively.

This strategic move aligns with Epigral’s efforts to secure power for its future expansion projects while progressing towards its sustainability goals. The transaction has been carried out at arm’s length and does not require any regulatory approvals.

Epigral commissions India’s frst chlorotoluenes value chain facility in Dahej

Aman Shukla — Mon, 24 Mar 2025 08:13:40 +0000

Epigral has achieved a major milestone by commissioning India’s first Chlorotoluenes Value Chain Facility at its Dahej Complex in Gujarat on March 24, 2025. This cutting-edge facility enhances Epigral’s integrated manufacturing capabilities, reinforcing its leadership in the specialty chemicals sector.

The new facility will produce high-quality chlorotoluene-based intermediates, essential for the pharmaceutical and agrochemical industries. This development aligns with India’s growing focus on self-reliance in chemical manufacturing, reducing dependency on imports and boosting domestic supply chains.

In the exchange filing, Epigral shared, “The company has successfully commissioned India’s first Chlorotoluenes Value Chain Facility at its Dahej Complex in Gujarat on 24th March, 2025. This facility will further strengthen Epigral’s integrated complex and will supply intermediates for pharmaceutical and agrochemical industries.”

Epigral’s investment in this state-of-the-art facility underscores its commitment to innovation, sustainability, and industry growth.

Epigral Q3 Results: Revenue up 36.8% YoY to Rs 645.24 crore, Net Profit up 111% YoY

Aditya Bhagchandani — Mon, 27 Jan 2025 08:26:18 +0000

Epigral Limited (formerly Meghmani Finechem Limited) has released its consolidated financial results for the quarter ended December 31, 2024, showcasing a solid performance with notable year-on-year (YoY) growth across key metrics.

Revenue Growth
The company reported a revenue from operations of ₹645.24 crore, reflecting a 36.8% YoY increase from ₹471.52 crore in the same quarter last year. Sequentially, revenue grew by 3.1% compared to ₹626.06 crore in the previous quarter.

Profitability Metrics
The net profit for the quarter stood at ₹103.63 crore, marking an impressive 111.3% YoY growth compared to ₹49.08 crore in Q3 FY24. On a quarter-on-quarter (QoQ) basis, net profit rose by 27.9% from ₹81.30 crore reported in the September 2024 quarter.

The company’s profit before tax (PBT) increased significantly to ₹153.62 crore, up 107.3% YoY from ₹73.93 crore in Q3 FY24.

Dividend Announcement
The company declared an interim dividend of ₹2.50 per equity share (25% of the face value of ₹10) for the financial year 2024-25. The record date for determining the eligibility of shareholders to receive the dividend has been fixed as Friday, February 7, 2025. The dividend will be credited or dispatched within 30 days of the declaration as per the provisions of the Companies Act, 2013.

Expense Analysis
Total expenses for the quarter were ₹495.57 crore, up 24% YoY from ₹399.82 crore in the corresponding period last year. However, the expenses decreased slightly on a sequential basis compared to ₹507.20 crore in the previous quarter.

Key Highlights

EBITDA Margin: The company continued to show efficient cost management, boosting overall profitability.
Power and Fuel Costs: These were reported at ₹30.78 crore, increasing slightly from ₹30.06 crore in the same period last year.
Employee Benefits Expense: The expense rose to ₹29.09 crore, up 29.3% YoY from ₹22.50 crore in Q3 FY24.

Outlook
Epigral Limited’s consistent revenue growth and improved profitability reflect its operational efficiency and robust market demand. The company’s focus on cost management and strategic investments positions it well for sustained growth in the coming quarters.

Disclaimer: The above information is for informational purposes only and should not be considered investment advice. Always consult a financial advisor before making investment decisions.

Epigral shares surge 4% after company expands CPVC capacity

Aditya Bhagchandani — Wed, 03 Apr 2024 09:29:03 +0000

Epigral Limited shares surged over four percent on Wednesday, April 3. This rally was fueled by the successful commissioning of an additional 45,000 TPA (tonnes per annum) capacity for CPVC (Chlorinated Polyvinyl Chloride) resin at its Dahej facility in Gujarat. With this expansion, Epigral’s total CPVC resin capacity has reached 75,000 TPA, establishing it as the largest CPVC resin facility globally at a single location.

Alongside expanding its CPVC resin capacity, Epigral is diversifying into CPVC compound production with a projected capacity of 35,000 TPA. This project is currently underway and is expected to become operational by the first quarter of the financial year 2025.

As of 2:50 pm, Epigral’s shares were trading 3% higher at ₹1,362.90 on NSE.

CPVC resin and compound play crucial roles in producing CPVC pipes and fittings, known for their exceptional heat and chemical resistance, making them ideal for various domestic and industrial applications. The company stated that India’s demand for CPVC stands at around 250,000 tonnes per annum and continues to grow steadily, with an anticipated annual growth rate ranging between 10% and 13%.